Literature DB >> 28149155

Therapeutic Drug Monitoring on the Safety of Sirolimus in Transplant Patients.

Edibe Minareci1.   

Abstract

Entities:  

Year:  2016        PMID： 28149155      PMCID： PMC5268612          DOI： 10.5152/eurasianjmed.2016.0034

Source DB:  PubMed          Journal:  Eurasian J Med        ISSN： 1308-8734


× No keyword cloud information.
  4 in total

1.  Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Authors:  Ezra E W Cohen; Kehua Wu; Christine Hartford; Masha Kocherginsky; Kimberly Napoli Eaton; Yuanyuan Zha; Anitha Nallari; Michael L Maitland; Kammi Fox-Kay; Kristin Moshier; Larry House; Jacqueline Ramirez; Samir D Undevia; Gini F Fleming; Thomas F Gajewski; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-08-07       Impact factor: 12.531

Review 2.  Sirolimus and everolimus in kidney transplantation.

Authors:  Dirk Jan A R Moes; Henk-Jan Guchelaar; Johan W de Fijter
Journal:  Drug Discov Today       Date:  2015-06-04       Impact factor: 7.851

3.  New-Onset Diabetes Mellitus Associated with Sirolimus Use in Renal Transplant Recipients.

Authors:  Vural Taner Yilmaz; Huseyin Kocak; Ayhan Dinckan; Ramazan Cetinkaya
Journal:  Eurasian J Med       Date:  2015-10

4.  Drug Interaction between Sirolimus and Ranolazine in a Kidney Transplant Patient.

Authors:  Joanna C Masters; Mita M Shah; Ashley A Feist
Journal:  Case Rep Transplant       Date:  2014-01-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.